Autophagy inhibition to augment mTOR inhibition: A phase I/II trial of everolimus and hydroxychloroquine in patients with previously treated renal cell carcinoma

Naomi B. Haas*, Leonard J. Appleman, Mark Stein, Maryann Redlinger, Melissa Wilks, Xiaowei Xu, Angelique Onorati, Anusha Kalavacharla, Taehyong Kim, Chao Jie Zhen, Sabah Kadri, Jeremy P. Segal, Phyllis A. Gimotty, Lisa E. Davis, Ravi K. Amaravadi

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

97 Scopus citations

Fingerprint

Dive into the research topics of 'Autophagy inhibition to augment mTOR inhibition: A phase I/II trial of everolimus and hydroxychloroquine in patients with previously treated renal cell carcinoma'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science